Status:
COMPLETED
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
Lead Sponsor:
Pfizer
Conditions:
Healthy Participants
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be...
Eligibility Criteria
Inclusion
- Healthy Chinese participants
- No clinical relevant abnormalities
- Body mass index (BMI):17.5-28
Exclusion
- Any clinical significant illness
- History of alcohol abuse
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days prior the first study dose
- Abnormal clinical lab tests: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, estimated glomerular filtration rate (eGFR)
- Abnormal vital signs, such 12-electrocardiogram (ECG), blood pressure and pulse rate
- Blood donation within 60 days
- History of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCVAb)
- Other medical or psychiatric may inappropriate for the study
Key Trial Info
Start Date :
March 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 21 2022
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05339334
Start Date
March 10 2022
End Date
April 21 2022
Last Update
October 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital,Fudan University
Shanghai, Shanghai Municipality, China, 201107